Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Some occasional discounts and promotions can substantially reduce the price, which can make their products more accessible for those who might otherwise be priced out
Potenciadores qumicos de permeacin : Sustancias que temporalmente alteran la estructura de la barrera cutnea
Keytruda (pembrolizumab) Disease area(s): Oncology Manufacturer(s): Merck 2024 Sales (USD): $29.48 billion Why it sold so well: Mercks flagship cancer immunotherapy Keytruda achieved expected, remarkable success in 2024, with global sales reaching $29.48 billion an 18% increase from the previous year and accounting for 46% of the companys total revenue
Do not stop treatment without medical advice, as abrupt discontinuation can worsen glycaemic control
US$ 20.80
US$ 25.96
US$ 28.69
US$ 25.24
US$ 21.92
/assets/images/provider/photos/2766296.jpeg)
US$ 28.24
